EP1067920A4 - METHODS AND COMPOSITIONS FOR REDUCING THE INHIBITION OF COLLAGEN SYNTHESIS INDUCED BY UV RADIATION IN HUMAN SKIN - Google Patents

METHODS AND COMPOSITIONS FOR REDUCING THE INHIBITION OF COLLAGEN SYNTHESIS INDUCED BY UV RADIATION IN HUMAN SKIN

Info

Publication number
EP1067920A4
EP1067920A4 EP99918456A EP99918456A EP1067920A4 EP 1067920 A4 EP1067920 A4 EP 1067920A4 EP 99918456 A EP99918456 A EP 99918456A EP 99918456 A EP99918456 A EP 99918456A EP 1067920 A4 EP1067920 A4 EP 1067920A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
radiation
compositions
reducing
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99918456A
Other languages
German (de)
French (fr)
Other versions
EP1067920A1 (en
Inventor
Gary J Fisher
John J Voorhees
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of EP1067920A1 publication Critical patent/EP1067920A1/en
Publication of EP1067920A4 publication Critical patent/EP1067920A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99918456A 1998-04-02 1999-04-02 METHODS AND COMPOSITIONS FOR REDUCING THE INHIBITION OF COLLAGEN SYNTHESIS INDUCED BY UV RADIATION IN HUMAN SKIN Withdrawn EP1067920A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8043798P 1998-04-02 1998-04-02
PCT/US1999/007267 WO1999051220A1 (en) 1998-04-02 1999-04-02 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin
US80437P 2008-07-14

Publications (2)

Publication Number Publication Date
EP1067920A1 EP1067920A1 (en) 2001-01-17
EP1067920A4 true EP1067920A4 (en) 2003-01-02

Family

ID=22157383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99918456A Withdrawn EP1067920A4 (en) 1998-04-02 1999-04-02 METHODS AND COMPOSITIONS FOR REDUCING THE INHIBITION OF COLLAGEN SYNTHESIS INDUCED BY UV RADIATION IN HUMAN SKIN

Country Status (11)

Country Link
EP (1) EP1067920A4 (en)
JP (1) JP2002510621A (en)
KR (1) KR20010042422A (en)
CN (1) CN1303282A (en)
AR (1) AR018826A1 (en)
AU (1) AU740569B2 (en)
BR (1) BR9909899A (en)
CA (1) CA2326507A1 (en)
HK (1) HK1038514A1 (en)
TW (1) TWI234455B (en)
WO (1) WO1999051220A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100377397B1 (en) * 1999-12-23 2003-03-26 주식회사 대웅 Skin care composition containing retinol and epidermal growth factor
MXPA03000089A (en) * 2000-06-26 2004-09-13 Univ Michigan Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin.
JP4612180B2 (en) * 2000-12-19 2011-01-12 株式会社ヤクルト本社 Skin preparation
GB0319497D0 (en) * 2003-08-19 2003-09-17 Novartis Ag Organic compounds
KR100879558B1 (en) * 2007-07-31 2009-01-22 라이브켐 주식회사 Skin protection and improvement agent containing dibenzo 함유 para­dioxin derivative as an active ingredient
WO2009122540A1 (en) * 2008-03-31 2009-10-08 株式会社資生堂 Wrinkle-preventing or improving agent for oral, injection or external skin application and cosmetic method
KR20160003188A (en) * 2008-03-31 2016-01-08 가부시키가이샤 시세이도 Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method
EP2153814A1 (en) 2008-08-05 2010-02-17 Isdin S.A. Use of compositions comprising urea
EP2153815A1 (en) 2008-08-05 2010-02-17 Isdin S.A. Use of urea containing compositions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
JPS6061513A (en) * 1983-09-14 1985-04-09 Sansho Seiyaku Kk Cosmetic
EP0358528A2 (en) * 1988-09-09 1990-03-14 Unilever Plc Cosmetic composition
JPH02142713A (en) * 1988-11-25 1990-05-31 Shiseido Co Ltd External preparation for skin
JPH08245362A (en) * 1995-03-08 1996-09-24 Seikagaku Kogyo Co Ltd External agent for preventing ultraviolet damage
EP0781551A1 (en) * 1995-12-29 1997-07-02 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
WO1997046208A2 (en) * 1996-06-07 1997-12-11 Mt. Sinai School Of Medicine Of The City Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1998030215A1 (en) * 1997-01-13 1998-07-16 Cilag Ag Liposome-based topical tretinoin formulation
WO1999036050A1 (en) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810489A (en) * 1986-12-04 1989-03-07 Bristol-Myers Company High oil phase pharmaceutical vehicles and sunscreen compositions having waterproof sun protection factors
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
US5690947A (en) * 1996-08-30 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
JPS6061513A (en) * 1983-09-14 1985-04-09 Sansho Seiyaku Kk Cosmetic
EP0358528A2 (en) * 1988-09-09 1990-03-14 Unilever Plc Cosmetic composition
JPH02142713A (en) * 1988-11-25 1990-05-31 Shiseido Co Ltd External preparation for skin
JPH08245362A (en) * 1995-03-08 1996-09-24 Seikagaku Kogyo Co Ltd External agent for preventing ultraviolet damage
EP0781551A1 (en) * 1995-12-29 1997-07-02 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
WO1997046208A2 (en) * 1996-06-07 1997-12-11 Mt. Sinai School Of Medicine Of The City Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1998030215A1 (en) * 1997-01-13 1998-07-16 Cilag Ag Liposome-based topical tretinoin formulation
WO1999036050A1 (en) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CARCINOGENESIS. ENGLAND JAN 1996, vol. 17, no. 1, January 1996 (1996-01-01), pages 73 - 77, ISSN: 0143-3334 *
DATABASE MEDLINE [online] January 1996 (1996-01-01), WEI H ET AL: "Inhibition of UV light- and Fenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein.", XP002218353, Database accession no. NLM8565140 *
DATABASE WPI Section Ch Week 198520, Derwent World Patents Index; Class D21, AN 1985-120196, XP002218354 *
DATABASE WPI Section Ch Week 199648, Derwent World Patents Index; Class B05, AN 1996-482093, XP002202753 *
FISHER G J ET AL: "RETINOIC ACID INHIBITS INDUCTION OF C-JUN PROTEIN BY ULTRAVIOLET RADIATION THAT OCCURS SUBSEQUENT TO ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE PATHWAYS IN HUMAN SKIN IN VIVO", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 6, no. 101, 15 March 1998 (1998-03-15), pages 1432 - 1440, XP001074731, ISSN: 0021-9738 *
GRIFFITHS CHRISTOPHER E M ET AL: "Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid).", NEW ENGLAND JOURNAL OF MEDICINE, vol. 329, no. 8, 1993, pages 530 - 535, XP000889997, ISSN: 0028-4793 *
KANG S ET AL: "PHOTOAGING AND TOPICAL TRETINOIN THERAPY, PATHOGENESIS, AND PREVENTION", ARCHIVES OF DERMATOLOGY, XX, XX, vol. 10, no. 133, October 1997 (1997-10-01), pages 1280 - 1284, XP008003909, ISSN: 0003-987X *
KLIGMAN L H ET AL: "TOPICAL RETINOIC ACID ENHANCES THE REPAIR OF ULTRAVIOLET DAMAGED DERMAL CONNECTIVE TISSUE", CONNECTIVE TISSUE RESEARCH, GORDON AND BREACH SCIENCE PUBLISHERS, US, vol. 12, 1984, pages 139 - 150, XP000576293, ISSN: 0300-8207 *
KLIGMAN L H: "PHOTOAGING MANIFESTATIONS, PREVENTION, AND TREATMENT", DERMATOLOGIC CLINICS, W.B. SAUNDERS CO., LONDON, GB, vol. 3, no. 4, July 1986 (1986-07-01), pages 517 - 528, XP008003894, ISSN: 0733-8635 *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 386 (C - 0750) 21 August 1990 (1990-08-21) *
SCHWARTZ E ET AL: "TOPICAL ALL-TRANS RETINOIC ACID STIMULATES COLLAGEN SYNTHESIS IN-VIVO", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 96, no. 6, 1991, pages 975 - 978, XP008003907, ISSN: 0022-202X *
See also references of WO9951220A1 *
WANG Y ET AL: "Inhibition of ultraviolet B-induced c-fos and c-jun expression in vivo by soybean isoflavone genistein.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 270, XP008009935, ISSN: 0197-016X *
WEI HUACHEN ET AL: "Protection of ultraviolet B radiation-induced photodamage in hairless mouse and human skin by isoflavone genistein.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 108, no. 4, 1997, Annual Meeting of the Society for Investigative Dermatology;Washington, D.C., USA; April 23-27, 1997, pages 666, XP008009949, ISSN: 0022-202X *
WEISS J S ET AL: "TOPICAL TRETINOIN IMPROVES PHOTOAGED SKIN A DOUBLE-BLIND VEHICLE-CONTROLLED STUDY", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 259, no. 4, 22 January 1988 (1988-01-22), pages 527 - 532, XP000576282, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
AU3637499A (en) 1999-10-25
WO1999051220A1 (en) 1999-10-14
TWI234455B (en) 2005-06-21
BR9909899A (en) 2000-12-26
CA2326507A1 (en) 1999-10-14
EP1067920A1 (en) 2001-01-17
JP2002510621A (en) 2002-04-09
KR20010042422A (en) 2001-05-25
HK1038514A1 (en) 2002-03-22
WO1999051220A9 (en) 2000-04-27
CN1303282A (en) 2001-07-11
AU740569B2 (en) 2001-11-08
AR018826A1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
EP0906077A4 (en) SKIN CARE COMPOSITION
GB2308811B (en) Use of vitamin C or derivatives or analogues thereof for promoting skin elastin synthesis
IL141429A0 (en) Compositions and methods for treatment of mitochondrial diseases
FR2751874B1 (en) NEW COSMETIC COMPOSITIONS TO ENHANCE AND BRIGHTEN SKIN
MA22240A1 (en) SKIN CARE COMPOSITIONS
DE60043692D1 (en) ACYL DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO VLA-4
EP0884996A4 (en) SKIN CARE COMPOSITIONS
PT914118E (en) SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND ITS USE AS PHARMACEUTICAL CHELATES OF METALS
BR9607726A (en) Device and method for retraction of gingival tissue
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
FR2688136B1 (en) COSMETIC COMPOSITION CONTAINING MELANIC PIGMENTS IN ASSOCIATION WITH CERTAIN TOCOPHEROLS, AND METHOD FOR PROTECTING THE SKIN, HAIR, MUCOSA AND COSMETIC COMPOSITIONS.
ITMI991794A0 (en) METHOD AND EQUIPMENT FOR DYNAMIC EXPOSURE TO ULTRAVIOUS RAYS
DE69611444D1 (en) AMID DERIVATIVES AND COMPOSITIONS FOR EXTERNAL SKIN AND HAIR CARE
FR2687572B1 (en) USE OF CERTAIN FLAVONOUIDS IN COSMETIC COMPOSITIONS, AND METHOD FOR PROTECTING THE SKIN, ITS PHANERES AND COSMETIC COMPOSITIONS.
FR2757370B1 (en) IMPROVED PLATE OF FEMALE OSTEOSYNTHESIS
EP1067920A4 (en) METHODS AND COMPOSITIONS FOR REDUCING THE INHIBITION OF COLLAGEN SYNTHESIS INDUCED BY UV RADIATION IN HUMAN SKIN
ITRM940570A0 (en) "L-CARNITINE SALT AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF SKIN DISEASES"
ZA969471B (en) Synthesis of quaternary melanin compounds and their use as hair dyes or for skin treatment
PL337064A1 (en) Method of and compositions for orally administering taxanes to human beings
FR2795639B1 (en) ARTIFICIAL SKIN COLORING COMPOSITIONS AND USES
FR2757635B1 (en) METHOD FOR EVALUATING UV-A DAMAGE TO THE SKIN
DE69925578D1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES RELATED TO EYE-BASED CELL-DISEASES
EP1214040A4 (en) USE OF ORANGE SKIN EXTRACTS IN THE PREVENTION AND TREATMENT OF CANCER
FR2723316B1 (en) SKIN DEPIGMENTING COMPOSITIONS AND PREPARATIONS FOR PHARMACEUTICAL OR COSMETIC USES
DK0700897T3 (en) L-carnitine salt and cosmetic and pharmaceutical preparations containing the same for the treatment of skin diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001030

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/20 A, 7A 61K 31/12 B, 7A 61K 31/235 B, 7A 61K 31/35 B, 7A 61K 31/17 B, 7A 61K 31/07 B, 7A 61K 31/52 B, 7A 61K 31/165 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021113

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060215